Serum and brain metabolomic study reveals the protective effects of Bai-Mi-Decoction on rats with ischemic stroke

Lingling Yang1†, Xiaojuan Su1†, Fangfang Lu1, Rong Zong1, Shuqing Ding1, Jing Liu1, Gideon Wilson1, Liuyan Li1, Youyue Yang1, Weibiao Wang1, Xiaoying Wang1, Jianyu Chen2* and Xueqin Ma1*

1Department of Pharmaceutical Analysis, Key Laboratory of Hui Ethnic Medicine Modernization, Ministry of Education, School of Pharmacy, Ningxia Medical University, Yinchuan, China, 2Fujian University of Traditional Chinese Medicine, Fuzhou, China

Bai-Mi-Decoction (BMD), which is composed of Eugenia caryophyllata, Myristica fragrans, Moschus berezovskii, and Crocus sativu, is a characteristic TCM multi-herb formula for brain disease. However, the mechanism of protective effects of BMD on ischemic stroke (IS) still has not been clarified. Our study is designed to elucidate the protective effects and underlying mechanisms of BMD on IS by employing pharmacodynamic and serum and brain metabolomic methods. In this experiment, 90 adult male Sprague–Dawley rats were randomly divided into the sham operation group (SHAM, vehicle), middle cerebral artery occlusion–reperfusion injury model group (MCAO/R, vehicle), positive control group (NMDP, 36 mg/kg/day nimodipine), and low (BMDL, 0.805 g/kg/day), moderate (BMDM, 1.61 g/kg/day), and high (BMDH, 3.22 g/kg/day) dosage of BMD prophylactic administration groups. The drugs were dissolved in 0.5% CMC-Na and orally administered to rats with equal volumes (100 g/ml body weight) once a day for 14 consecutive days. Neurological deficit score, cerebral infarct volume, change in body weight, and serum NO, SOD, MDA, GSH, and GSSG levels were determined. Pathological abnormalities using hematoxylin and eosin staining and the expression of VEGF, caspase-3, and NF-κB were analyzed. Furthermore, serum and brain metabolic profiles were explored to reveal the underlying mechanism using UHPLC-QTOF-MS/MS technology. BMD exhibited significant protective effects on IS.

Abbreviations: BMD, Bai-Mi-Decoction; CCA, common carotid artery; CMC-Na, carboxymethyl cellulose sodium; ECA, external carotid artery; GC-MS, gas chromatography–mass spectrometry; GSH, glutathione; GSSG, glutathiol; HE, hematoxylin and eosin; ICA, internal carotid artery; IS, ischemic stroke; LC-MS, liquid chromatography–mass spectrometry; MCA, middle cerebral artery; MCAO, middle cerebral artery occlusion; MCAO/R, middle cerebral artery occlusion–reperfusion injury model group; MDA, malondialdehyde; NF-xB, nuclear factor-xB; NMDP, nimodipine; NMR, nuclear magnetic resonance; NS, normal saline; NO, nitric oxide; OPLS-DA, orthogonal projections to latent structure discriminant analysis; PCA, principal component analysis; ROS, reactive oxygen species; SOD, superoxide dismutase; TCM, traditional Chinese medicine; TTC, triphenyltetrazolium chloride; UHPLC–MS, ultra-high performance liquid chromatography/mass spectrometry; VEGF, vascular endothelial growth factor; VIP, variable importance in the projection.
neuroprotective effects on MCAO/R rats. As compared to the MCAO/R model group, it could reduce the neurological deficit score and cerebral infarct volume, increase body weight, enhance GSH, SOD, and GSSG activities, and decrease NO and MDA contents of MCAO/R rats. Meanwhile, BMD could ameliorate pathological abnormalities of MCAO/R rats through reducing neuronal loss, vacuolated spaces, shrunken neurons, and destructed neuron structure, as well as regulating the expression of VEGF, caspase-3, and NF-κB. UHPLC-QTOF-MS/MS-based serum and brain metabolomics analysis found a total of 53 differential metabolites between MCAO/R and SHAM groups, of which 30 were significantly regulated by BMD intervention, and further metabolic pathway analysis implied that the protective effects were mainly associated with amino acid and glycerophospholipid metabolisms. Our pharmacodynamic and metabolomic results revealed the neuroprotective effects of BMD on MCAO/R rats, and the underlying mechanisms were probably related to amino acid and glycerophospholipid metabolisms.

KEYWORDS
Bai-Mi-Decoction, ischemic stroke, pharmacodynamics, metabolomics, UHPLC-QTOF-MS/MS

1 Introduction

Stroke is the second largest main cause of mortality and long-term disability worldwide, and it has developed as a major contributor for the overall global burden of healthy systems (Qureshi et al., 2016). Particularly in China, an estimated one million people died from stroke each year (Gairolla et al., 2017). The proportion of ischemic stroke (IS) accounts for approximately 85% of all stroke cases worldwide (Strong et al., 2007), which occurs when hypoxia is induced by the lack of blood flow in the middle cerebral artery of the brain (Cheon et al., 2018). Although the pathological process of IS was complex and still not clear, it was proved to be associated with energy depletion, inflammation, neuronal apoptosis, ionic imbalance, blood–brain barrier disruption, angiogenesis, oxidative stress, and neurological injury (Dirnagl et al., 1999; Cheon et al., 2018). Currently, thrombolytic therapy and antithrombic and antiplatelet medication were clinically used for treating IS (Fjetland et al., 2015; Chen et al., 2019a). Unsatisfactorily, the clinical application of these drugs has some limitations due to the narrow therapeutic time window and various kinds of adverse effects. Currently, with the increased acceptance of combination therapies for the treatment of complicated diseases, the development of traditional Chinese medicine (TCM) with characteristics of multi-components and multi-mechanisms have become an emerging trend.

Bai-Mi-Decoction (BMD) is a typical TCM multi-herb formula for brain diseases officially recorded in the Huihui Medical Formulary. It is composed of four herbs: Eugenia caryophyllata Thunb (EC), Myristica fragrans Houtt (MF), Moschus berezovskii Flerov (MB), and Crocus sativus L (CS). It had been used to cure paralysis, improve facial paralysis, and relieve physical weakness in clinical practice in the ancient time. The modern clinical practice revealed that BMD could improve the neurological function and daily living ability of patients with IS (Song, 2007). However, due to the complexity of chemical compositions of BMD and pathological processes of IS, the underlying mechanisms of BMD has still not been elucidated.

In the present study, the protective effects and related mechanisms of BMD on IS were performed via pharmacodynamic and metabolomic strategies, respectively. By using the middle cerebral artery occlusion–reperfusion injury (MCAO/R) rat model and UHPLC-QTOF-MS/MS technique, the neuroprotective effects of BMD on MCAO/R rats were estimated, the differential metabolites of rat’s serum and brain were employed using metabolomic analysis, and the possible mechanisms which were related to antioxidant, amino acid, and glycerophospholipid metabolisms were elucidated.

2 Materials and methods

2.1 Materials and reagents

Eugenia caryophyllata Thunb (EC), Myristica fragrans Houtt (MF), Moschus berezovskii Flerov (MB), and Crocus sativus L (CS), which were identified by Dr. Lin Dong (Department of Pharmacognosy, Ningxia Medical University), were purchased from Ming De Chinese Herbal Pieces Co., Ltd. (Ningxia, China), and the specimens (#20150701, #20150703, #20150704, and #20150705) were preserved in the Department of Pharmacy, Ningxia Medical University. Nimodipine was provided by Bayer Healthcare Co., Ltd. (Germany); nitric oxide (NO, 20181221), super oxide dismutase (SOD, 20181221), malondialdehyde (MDA, 20190308), glutathione (GSH, 20181218), and glutathiol (GSSG, 20190306) reagent kits were offered by the...
Institute of Nanjing Jiancheng Biological Engineering (Nanjing, China); antibodies of vascular endothelial growth factor (VEGF, ab32152), caspase-3 (ab32351), and nuclear factor-κB (NF-κB, ab32536) were obtained from Abcam Co., Ltd (Shanghai, China); acetonitrile, methanol, isopropanol, and formic acid of HPLC grade were obtained from Fisher Scientific (Nepean, Canada) and Sigma–Aldrich (St. Louis, United States); ultrapure water was obtained from Watsons Water (Guangzhou, China); and triphenyltetrazolium chloride (TTC) was obtained from Suolaibao Engineering (Beijing, China). All the other reagents were of analytical grade.

2.2 Preparation of BMD

BMD was prepared according to the records of the Huihui Medical Formulary and clinic. Volumes of 225 g EC and 750 g MF were powdered, mixed fully, and extracted three times by using the reflux method with 75% ethanol for 2 h each time. Then, the extractions were filtrated, merged, and ethanol was removed under reduced pressure concentrate below 60°C to obtain extracts. Finally, the extracts were fully mixed with powdered MB (7.5 g) and CS (225 g) to obtain BMD extract. For animal experiments, BMD extract was suspended in 0.5% carboxymethyl cellulose sodium (CMC-Na) aqueous solution and orally administered to rats.

2.3 Experimental animals and MCAO/R model establishment

All animal experiments were conducted in accordance with the laboratory animal principles and were carried out under the guidelines of the Bioethics Committee of Ningxia Medical University (license number: NXMU-2018092). A total of 90 adult male Sprague–Dawley rats (220–250 g) were provided by the Laboratory Animal Center of Ningxia Medical University (animal certification number: SCXK (Ning) 2015-0001). All animals were acclimated for 1 week in regulated polypropylene cages (three rats/cage) and standard specific pathogen-free environment (24.0 ± 0.5°C, 50%–60% humidity) with light and dark illumination cycles (12 h: 12 h). Rodent chow and water were given ad libitum. Then, the rats were randomly divided into six groups with 15 rats in each group: the sham operation group (SHAM, vehicle), MCAO/R model group (MCAO/R, vehicle), positive control group (NMDP, 36 mg/kg/day nimodipine), BMD low-dosage group (BMDL, 0.805 g/kg/day), BMD moderate-dosage group (BMDM, 1.61 g/kg/day), and BMD high-dosage group (BMDH, 3.22 g/kg/day). The ratio of MF:EC:CS:MB in BMD was 10:3:3:0.1, and 0.5% CMC-Na was used as a vehicle with an equal volume (100 g/ml body-weight) for each rat. All animals were administered orally once per day for 14 consecutive days.

After 14 days of prophylactic intervention, the MCAO/R-induced IS model was performed according to Nagasawa and Kogure (1989). Briefly, the rats were first anesthetized with 7% chloral hydrate (100 mg/kg, i.p.), and then the right common carotid artery (CCA), internal carotid artery (ICA), and external carotid artery (ECA) were exposed and isolated from subcutaneous muscle tissue and fascia through a neck incision (1.5–2 cm) with the CCA and ICA temporarily clipped with arterial clipping; a nylon monofilament suture (0.2 mm) with a slightly marked and rounded tip was inserted into the ECA and gently advanced from the ICA to the opening of the middle cerebral artery. The distance from the bifurcation of the ECA to the tip of the suture ranged from 18–20 mm. After 2 h of sustained MCAO, reperfusion was performed by the inserted nylon monofilament structure pulled out to restore the blood flow, and the time of reperfusion was 24 h. The SHAM operation group rats received the same surgical procedures except that the occluding monofilament was not inserted. All of the aforementioned procedures were performed in a sterile environment.

2.4 Neurological deficit measurements

The scores of neurological deficit of each rat was evaluated by employing Longa’s five-level neurological severity score, 24 hours after reperfusion: 0, no deficit; 1, failure to extend the right paw; 2, circling to the contralateral side uncontrollably; 3, falling to the contralateral side freely; and 4, unable to walk spontaneously or loss of consciousness.

2.5 Infarct volume measurement

Cerebral infarct volume was determined by using the 2,3,5-triphenyltetrazolium chloride (TTC) staining method. The rats were anesthetized, the blood samples were obtained from the femoral artery, the brain was removed immediately and cut into five coronal slices averagely, and then the slices were immersed in 2% TTC for 45 min at 37°C in the dark and turned them every 15 min. The results were analyzed by measuring the normal (red) and infarct volume ratio of the brain tissue (white). The cerebral infarction volume ratio was calculated using the following formula: the infarcted volume of the brain/the total volume of the brain × 100%.

2.6 Biochemical, histopathological, and immunohistochemical examinations

The levels of oxidative stress-related index including NO, SOD, MDA, GSH, and GSSG were analyzed by employing the
corresponding reagent kits. For histopathological examination, the brain tissue was fixed in 4% paraformaldehyde for 12 h, and then the brain slices were dehydrated, paraffin-embedded, sectioned, and stained with hematoxylin and eosin (HE). For immunohistochemical examination, the brain slices were dehydrated, paraffin-embedded, and sectioned, and then the levels of VEGF, caspase-3, and NF-κB were determined by using a microscope. Image analysis software was used to extract details from the images.

2.7 Metabolomic analysis

2.7.1 Sample preparation

Serum samples were obtained by centrifuging the blood samples at 4,000 rpm for 15 min, and the supernatants were collected, whereas brain tissues were placed in normal saline (NS) to remove the residual blood, and then the serum and brain samples were frozen at −80°C until analysis.

For metabolomic analysis, serum and brain samples were first re-dissolved at ambient temperature before preparation; 100 μL of each serum sample was added to 600 μL of acetonitrile, vibrated for 3 min, and centrifuged at 13,000 rpm for 10 min at 4°C, and then the supernatant was collected. The fully thawed brain was weighed precisely, and an equal weight of NS was added and grinded to obtain brain tissue homogenate. Then, 100 μL of each brain homogenate was added to 200 μL of methanol–acetonitrile solution (1:1), vibrated for 3 min, and centrifuged at 13,000 rpm for 10 min at 4°C, and the supernatant was collected. Ultimately, 1 μL aliquot of the supernatant of serum and brain samples was directly injected to UHPLC-QTOF-MS/MS for data acquisition. Meanwhile, the serum and brain quality control (QC) samples were, respectively, prepared by taking 10 μL of each sample and mixing the aliquots together, and then the QC samples were injected at regular intervals (every 10 samples) throughout the analytical run to monitor the stability from the beginning to ending of the analysis.

2.7.2 UHPLC-QTOF-MS/MS conditions

UHPLC analysis was performed on an Agilent 1290 UHPLC system using a ZORBAX RRHD Eclipse Plus C18 column (50 mm × 2.1 mm, 1.8 μm), and the mobile phase consisted of A (0.1% formic acid in water) and B (0.1% formic acid in acetonitrile), with a gradient elution as follows: 0–1 min: 99–80% A; 1–5 min: 80–50% A; 5–10 min: 50–30% A; 10–15 min: 30–15% A; 15–16 min: 15–1% A; 16–17.5 min: 1%
A: 17.5–18.5 min: 1–99% A; and 18.5–20 min: 99% A. The column temperature was maintained at 35°C, and flow rate was 0.2 ml/min. Mass spectrometry (MS) analysis was performed on an Agilent 6545 Q-TOF instrument by employing an electrospray ionization (ESI) source in both positive and negative modes. The ionization source conditions were set as follows: capillary voltage of 4.0 kV; source temperature of 120°C; desolvation temperature of 350 °C; sampling cone voltage of 65 V; trap collision energy of 6.0 V; trap gas flow of 12 ml/min; atomizer pressure of 241.3 kPa; fragmentor of 130 V; and spray pressure of 40 psi; the data were collected from m/z 100 Da–3,000 Da.

2.7.3 Data processing and pattern recognition analysis

The original datasets of all samples were first converted into m/z. The data were formatted using Agilent MassHunter Qualitative software and then imported to the R software package for peak detection, identification, alignment, and normalization. The retention time, peak area, and m/z data of each peak were

FIGURE 2
Effect of BMD on the markers of oxidative stress (n = 8) including NO, SOD, MDA, GSH, and GSSG. (A) NO. (B) SOD. (C) MDA. (D) GSH. (E) GSSG. Data were expressed as the mean ± SD. *p < 0.05, **p < 0.01 relative to the MCAO/R group; #p < 0.05, ##p < 0.01 relative to the SHAM group.
collected. SIMCA (version 14.1, Umetrics AB, Umea, Sweden) was adopted for multivariate statistical analysis of the normalized data matrices: principal component analysis (PCA) and orthogonal projections to latent structure discriminant analysis (OPLS-DA). OPLS-DA modeling analysis was implemented for the first principal component, and the model quality was verified by seven-fold cross validation. Following this, the permutation test was employed to change the sequence of the classified variable Y randomly and repeatedly (200 times) to obtain different random Q² values, so as to further evaluate the effectiveness of the model. The variable importance in the projection (VIP) value was obtained from the OPLS-DA model. The univariate analysis \( t \)-test was performed by employing SPSS (18.0). Metabolite peaks with a VIP value greater than 1 and \( p \)-value less than 0.05 were considered significant differential metabolites. The relevant metabolic pathways were analyzed and identified using online databases, including HMDB, KEGG, and MetaboAnalyst.

### 2.8 Statistical analysis

All of the experimental results were described as the mean ± SD and were analyzed using SPSS software (version 18.0, IBM SPSS Statistics, IBM Corp., Armonk, New York, NY, United States). Data were performed using a \( t \)-test and one-way analysis of variance (ANOVA). The \( p \)-value less than 0.05 was considered statistically significant.

### 3 Results

#### 3.1 Effect of BMD on cerebral infarction

Neurological deficit score and cerebral infarct volume were the two most important evaluation indexes for brain injury. As shown in Figure 1, at 24 h after reperfusion, both the neurological deficit score and cerebral infarct volume were significantly increased in the MCAO/R model group compared to the SHAM group rats (\( p < 0.001 \)). BMD treatment markedly decreased the neurological deficit score and the cerebral infarct volume of MCAO/R rats independent of the dosage used. Moreover, to further evaluate whether BMD possessed the protective effects on MCAO/R rats, the body weight change of rats was evaluated. Despite having a similar environment after the surgery, the changes in body weight of rats in the MCAO/R group were significantly more than those in the SHAM rats (\( p < 0.001 \)). On the contrary, these changes were all significantly reduced after BMD intervention, and the organ coefficients of the heart, liver, spleen, lung, and kidney exhibited no significant difference in all groups.

#### 3.2 Effect of BMD on the markers of oxidative stress

The results from NO, SOD, MDA, GSH, and GSSG assessments indicated that BMD played a certain role in regulating the markers of oxidative stress. As compared with
the SHAM group, the levels of serum NO, MDA, and GSSG were evidently increased, and the contents of SOD and GSH were significantly decreased (Figure 2). Concerning the NO, MDA, and GSSG levels, a declining trend (but no statistically significant difference) in the GSSG level was observed in the BMDL- and BMDH-treated groups as compared to the MCAO/R group, whereas BMD at all three dosages evidently declined the NO and MDA levels in the MCAO/R rats \( (p < 0.05) \). For SOD and GSH, as shown in Figure 2, significantly increased trends were obtained in the BMD intervention groups as compared to the MCAO/R model group except the high dosage of BMD which showed no significant change in the SOD level.

3.3 Effect of BMD on histopathological and immunohistochemical abnormality of brain tissue

Figure 3 shows the morphological features of neurons by H&E staining. In the SHAM group, the frame of the brain tissue was clear with no pathological abnormalities in the cerebral cortex. On the contrary, an obvious change was found in the MCAO/R model group, evidenced by the signs of neuronal loss, vacuolated spaces, and shrunk and disordered neurons. After the prophylactic administration, BMD remarkably ameliorated the aforementioned pathological abnormalities in the brain tissue of MCAO/R rats.

To further explain the neuroprotective effects of BMD on the abnormality of brain tissue, the levels of NF-κB, VEGF, and caspase-3 were detected using immunohistochemical examination. As shown in Figure 4, the expression of NF-κB and VEGF in the MCAO/R model group was obviously increased, and an increasing trend but no statistical significance of the caspase-3 level was observed in MCAO/R model rats as compared with SHAM rats. All BMD-treated rats showed significantly decreased NF-κB p65, VEGF, and caspase-3 levels as compared to MCAO/R model rats, indicating that less brain injury was obtained in MCAO/R rats upon BMD prophylactic administration.
3.4 Effect of BMD on differential metabolites

3.4.1 Validation of the UHPLC-QTOF-MS/MS analysis method

To verify the repeatability and stability of the UHPLC-QTOF-MS/MS metabolomic method, the representative TICs of the serum sample in positive and negative ion modes are shown in Supplementary Figures S1, S2, respectively. The relative standard deviations (RSDs) of the typical peak areas and retention times were all less than 15% in positive and negative modes (Supplementary Table S1), which indicated the suitability and reliability of our metabolomic method.

3.4.2 Multivariate data analysis for serum and brain samples

In order to explore the systemic changes in the metabolome of MCAO/R rats intervened with or without BMD, both serum and brain samples were employed for UHPLC-QTOF-MS/MS metabolomic analysis, by using positive and negative ion modes. As shown in Figure 5, SHAM, MCAO/R, and BMD groups were separated from each other in both positive and negative ion modes, suggesting that the endogenous metabolites among them were different. To discriminate the potential endogenous metabolites, the OPLS-DA model was constructed to investigate the pathogenesis of IS induced by MCAO/R and the neuroprotective mechanism of BMD. The OPLS-DA results of serum and brain metabolomic profiling are shown.
Moreover, the model quality was estimated by employing R^2Y and Q^2 values. Correspondingly, R^2Y and Q^2 were all bigger than 0.9, indicating good fitness and predictability of this model.

### 3.4.3 Potential endogenous metabolite identification and metabolic pathway analysis

By using the OPLS-DA model, the differential metabolites in serum and brain samples between SHAM and MCAO/R groups associated with IS were screened. Setting the significance level at p < 0.05 and VIP>1, 22 differential endogenous metabolites in serum samples (Table 1) and 31 endogenous metabolites in brain samples (Table 2) were identified. Subsequently, a Venn diagram was adopted to analyze overlapping endogenous metabolites in the serum and brain samples (Figure 8), and the results showed that l-valine, lysoPC (14:0/0:0), l-phenylalanine, l-tryptophan, and dihomo-gamma-linolenic acid could be detected in both serum and brain samples. In addition, among these 53 differential endogenous metabolites, 30 metabolites in the MCAO/R rats were restored after administration of BMD, specifically 10 of them were found in serum and 20 were found in the brain (Figures 9, 10).

![Figure 6](image-url)

**FIGURE 6**

OPLS-DA score plots, S-plots, and permutation validation of serum samples. (D–F) OPLS-DA score plots of SHAM, MCAO/R, BMDL, BMDM, and BMDH in the positive mode; (G–I) OPLS-DA score plots of SHAM, MCAO/R, BMDL, BMDM, and BMDH in the negative mode; (A,G) OPLS-DA score plots of SHAM and MCAO/R in positive and negative modes, respectively; (B,H) S-plots of SHAM and MCAO/R in positive and negative modes, respectively; (C, I) permutation validation of SHAM and MCAO/R in positive and negative modes, respectively (n = 8).
intervention, the main biological metabolic pathway analysis was performed using the MetaboAnalyst 5.0 online database based on the identified differential metabolites in serum and brain samples. The results are shown in Figure 12, where 30 metabolites restored by BMD were associated with seven main metabolisms, and they were phenylalanine metabolism, histidine metabolism, tryptophan metabolism, arginine and proline metabolism, glycerophospholipid metabolism, fatty acid biosynthesis, and aminoacyl-tRNA biosynthesis. The mechanism analysis of the differential metabolites with the corresponding pathways is shown in Figure 13.

4 Discussion

Stroke is a serious medical emergency worldwide, ranking second only to cancer as a cause of death (Ouk et al., 2019). IS, transient IS, and hemorrhagic stroke are the three types of stroke, and among them, IS was thought to be generally caused by vascular obstruction, which brings out severe nerve injury (Chen et al., 2021). Owing to its high mortality and disability, an early diagnosis and intervention are of great importance to decline the damage of brain tissue (Yang et al., 2021).

BMD is a classic TCM formula, which was traditionally used to relieve physical weakness and improve facial paralysis of IS.
To confirm the protective effects of BMD, the main pharmacodynamic features such as neurological deficit score, cerebral infarct volume, and body weight change of MCAO/R rats were analyzed, and all of the results proved the protective efficacy of BMD on IS. Biochemical index examination revealed that BMD could regulate the levels of NO, SOD, MDA, GSH, and GSSG, consequently alleviating the oxidative stress injury. IS was defined as a pathological condition which related to a redox imbalance, the presence of oxidative stress was a great contributor to the pathophysiology of ischemia/reperfusion injuries (Chehaibi et al., 2016; Jurcau and Ardelean, 2021), and the oxidative stress was considered one of the earliest

| No. | Adduct Name | Formula | M/Z | RT/ min | HMDB | Fold | p-value | VIP | MCAO/ R vs. SHAM | Pathway |
|-----|--------------|---------|------|---------|-------|------|---------|-----|------------------|---------|
| 1   | L-Valine     | C₅H₁₀N₂O₂ | 118.0861 | 0.735   | HMDB0000883 | 1.3890 | 6.91E-05 | 1.3156 | Down | Amino acid metabolism |
| 2   | (2R)-2-Hydroxy-2-methylbutanenitrile | C₅H₁₀NO | 100.0759 | 1.897   | HMDB0060309 | 4.0741 | 6.12E-05 | 1.3693 | Down | Cyanosamoic acid metabolism |
| 3   | Indole-3-propionic acid | C₈H₁₀N₂O₂ | 190.0868 | 4.484   | HMDB002302 | 4.9225 | 3.79E-05 | 1.4864 | Down | Amino acid metabolism |
| 4   | LysoPC (14:0/0:0) | C₄₂H₆₀NO₇P | 468.3086 | 7.313   | HMDB0010379 | 2.0701 | 3.88E-04 | 1.2378 | Down | Glycerylphospholipid metabolism |
| 5   | LysoPC (20:5 (5Z,8Z,11Z,14Z,17Z)/0:0) | C₄₈H₇₀NO₇P | 542.3218 | 7.654   | HMDB0010397 | 1.7305 | 5.61E-07 | 1.5602 | Down | Glycerylphospholipid metabolism |
| 6   | LysoPE (0:0/18:0) | C₃₆H₅₀NO₇P | 482.3246 | 8.071   | HMDB0011129 | 2.4997 | 9.88E-06 | 1.4567 | Down | Glycerylphospholipid metabolism |
| 7   | Crustecdysone | C₄₂H₆₂NO₇P | 503.2980 | 8.303   | HMDB0030180 | 2.1569 | 4.33E-06 | 1.4408 | Down | Fatty acids and their derivatives |
| 8   | Phosphorylcholine | C₂₀H₃₂NO₇P | 184.0736 | 8.624   | HMDB0001565 | 1.4665 | 3.97E-04 | 1.2127 | Down | Glycerylphospholipid metabolism |
| 9   | LysoPC (18:1 (11Z)/0:0) | C₂₆H₅₂NO₇P | 522.3563 | 9.423   | HMDB0010385 | 2.2128 | 7.52E-06 | 1.4701 | Down | Glycerylphospholipid metabolism |
| 10  | Dihomo-gamma-linolenic acid | C₂₀H₃₂NO₇P | 307.2635 | 14.700  | HMDB0002925 | 2.4043 | 1.15E-07 | 1.6767 | Down | Glycerylphospholipid metabolism |
| 11  | Cer (d18:0/14:0) | C₃₂H₅₄NO₃ | 512.5030 | 16.348  | HMDB0011759 | 1.2193 | 1.65E-03 | 1.1095 | Down | Fatty acid metabolism |
| 12  | 27a-Hydroxy-8-dehydrocholesterol | C₂₉H₄₈O₃ | 401.3417 | 17.518  | HMDB0060132 | 3.7049 | 7.17E-07 | 1.5677 | Down | Steroid biosynthesis |
| 13  | 4a-Carboxy-4β-methyl-5α-chola-8-en-3β-ol | C₃₂H₆₅NO₃ | 445.3677 | 17.567  | HMDB0062384 | 1.5022 | 2.16E-04 | 1.2293 | Down | Cholesterol metabolism |
| 14  | Amphetamine | C₉H₁₃N | 136.1123 | 18.792  | HMDB0014328 | 1.0853 | 1.63E-07 | 1.6397 | Up | Pyrimidine metabolism |
| 15  | Sphinganine | C₁₈H₂₄NO₄ | 302.3058 | 18.858  | HMDB0000269 | 1.2181 | 6.09E-07 | 1.5410 | Down | Glycerylphospholipid metabolism |
| 16  | Benzylamine | C₇H₁₀N | 108.0809 | 18.877  | HMDB0033871 | 1.1455 | 2.61E-11 | 1.7798 | Up | Amino acid metabolism |
| 17  | L-Phenylalanine | C₆H₁₀N₂O₂ | 164.0714 | 1.843   | HMDB0000159 | 1.3774 | 8.37E-06 | 1.1886 | Up | Amino acid metabolism |
| 18  | L-Tryptophan | C₁₁H₁₂N₂O₂ | 203.0820 | 2.186   | HMDB0000929 | 1.3389 | 3.70E-04 | 1.0230 | Up | Amino acid metabolism |
| 19  | Indole | C₇H₇N | 116.0509 | 2.190   | HMDB0000738 | 1.3857 | 4.71E-05 | 1.1046 | Up | Amino acid metabolism |
| 20  | Benzoic acid | C₇H₆O₂ | 121.0291 | 2.551   | HMDB001870 | 1.1426 | 3.73E-08 | 1.4073 | Up | Amino acid metabolism |
| 21  | LysoPC (15:0/0:0) | C₂₂H₃₄NO₇P | 480.3909 | 8.907   | HMDB0010381 | 1.1617 | 1.47E-04 | 1.0301 | Down | Glycerylphospholipid metabolism |
| 22  | LysoPE (18:0/0:0) | C₂₂H₃₄NO₇P | 480.3909 | 10.735  | HMDB0011130 | 1.5225 | 4.62E-06 | 1.1642 | Down | Glycerylphospholipid metabolism |
## TABLE 2 Statistical analysis results of identified metabolite changes in the brain.

| No. | Adduct Name | Formula | M/Z  | RT/min | HMDB      | Fold | p-value | VIP      | MCAO/R vs. SHAM | Pathway                                           |
|-----|-------------|---------|------|--------|-----------|------|---------|---------|-----------------|---------------------------------------------------|
| 1   | L-Proline   | C₅H₉NO₂ | 116.0709 0.756 | HMDRD000162 | 1.3049 | 0.0000 | 1.2571 | Up       | Amino acid metabolism                               |
| 2   | L-Histidine | C₆H₉NO₂ | 156.0767 0.772 | HMDRD000177 | 1.2038 | 0.0002 | 1.0146 | Up       | Amino acid metabolism                               |
| 3   | L-Valine    | C₅H₉NO₂ | 118.0867 0.858 | HMDRD000883 | 1.2979 | 0.0000 | 1.2011 | Up       | Amino acid metabolism                               |
| 4   | Phenylpyruvic acid | C₆H₈O₃ | 165.0549 1.466 | HMDRD000205 | 1.3202 | 0.0000 | 1.1671 | Up       | Phenylpyruvic acid metabolism                      |
| 5   | trans-Cinnamic acid | C₆H₈O₂ | 149.0595 1.955 | HMDRD000930 | 1.2411 | 0.0000 | 1.1885 | Up       | Amino acid metabolism                               |
| 6   | L-Phenylalanine | C₅H₁₁NO₂ | 166.0864 1.955 | HMDRD001599 | 1.2343 | 0.0001 | 1.1657 | Up       | Amino acid metabolism                               |
| 7   | LysoPI (18:0/0:0) | C₉H₂₀O₁₂P | 601.3344 2.096 | HMDRD0240261 | 1.6325 | 0.0000 | 1.3573 | Up       | Glycerophospholipid metabolism                      |
| 8   | Leucylproline | C₉H₁₅NO₄ | 229.1549 2.146 | HMDRD0011175 | 1.3933 | 0.0000 | 1.1037 | Up       | Amino acid metabolism                               |
| 9   | 1H-Indole-3-carboxaldehyde | C₆H₉NO | 146.0602 2.228 | HMDRD0029737 | 1.3225 | 0.0000 | 1.1782 | Up       | Amino acid metabolism                               |
| 10  | N-Lactoylphenylalanine | C₆H₁₄NO₄ | 238.1077 3.276 | HMDRD0062134 | 1.6622 | 0.0000 | 1.3904 | Up       | Amino acid metabolism                               |
| 11  | LysoPC (14:0/0:0) | C₉H₁₄NO₄P | 468.3088 7.314 | HMDRD0010379 | 1.4068 | 0.0000 | 1.1772 | Up       | Glycerophospholipid metabolism                      |
| 12  | LysoPC (16:1 (9Z)/0:0) | C₁₂H₂₄NO₇P | 494.3243 7.813 | HMDRD0010383 | 1.3400 | 0.0002 | 1.1085 | Up       | Glycerophospholipid metabolism                      |
| 13  | LysoPC (20:4 (5Z,8Z,11Z,14Z)/0:0) | C₁₈H₃₄NO₇P | 544.3404 8.384 | HMDRD0010395 | 1.3553 | 0.0003 | 1.0765 | Up       | Glycerophospholipid metabolism                      |
| 14  | Palmitoleoyl ethanolamide | C₁₈H₃₅NO₂ | 298.2744 10.735 | HMDRD0013648 | 3.2995 | 0.0000 | 1.2799 | Up       | Fatty acid metabolism                               |
| 15  | N-Palmitoyl GABA | C₁₈H₃₉NO₃ | 342.3006 12.848 | HMDRD0062338 | 1.4290 | 0.0000 | 1.2852 | Up       | Phospholipid metabolism                             |
| 16  | Adrenoyl ethanolamide | C₂₀H₄₁NO₂ | 376.3216 13.470 | HMDRD0014365 | 6.8239 | 0.0000 | 1.2598 | Up       | Phospholipid metabolism                             |
| 17  | Styrene | C₂₄H₃₃ | 105.0699 14.651 | HMDRD0004240 | 1.1586 | 0.0021 | 1.0463 | Up       | Ethylbenzene degradation                            |
| 18  | N-M-Dimethylphosphinosine | C₂₀H₄₁NO₄ | 328.3216 15.218 | HMDRD0013645 | 11.7197 | 0.0000 | 1.4420 | Up       | Phospholipid metabolism                             |
| 19  | Dihomo-gamma-linolenic acid | C₂₀H₃₄O₂ | 307.2637 15.717 | HMDRD0002925 | 1.4151 | 0.0000 | 1.2222 | Up       | Linoleic acid metabolism                            |
| 20  | Phenylethylamine | C₁₈H₁₈N | 122.0967 18.716 | HMDRD0012275 | 1.5167 | 0.0000 | 1.4788 | Up       | Amino acid metabolism                               |
| 21  | Malic acid | C₇H₆O₅ | 133.0148 0.821 | HMDRD0000744 | 1.1945 | 2.31E-05 | 1.1197 | Up       | Pyruvate metabolism                                 |
| 22  | Gamma-glutamyl-Se-methylselenocysteine | C₁₈H₁₄N₆O₇Se | 311.0157 0.839 | HMDRD0010716 | 1.2357 | 1.47E-05 | 1.2170 | Down     | Selenocompound metabolism                           |
| 23  | Triazolam | C₁₄H₁₄N₄O₄ | 311.0157 0.839 | HMDRD0010716 | 1.2357 | 1.47E-05 | 1.2170 | Down     | Neuroactive ligand-receptor interaction             |
| 24  | Inosine | C₁₈H₃₄O₄N | 267.0734 1.718 | HMDRD000195 | 1.2029 | 1.12E-05 | 1.1971 | Down     | Amino acid metabolism                               |
| 25  | L-Phenylalanine | C₆H₁₄NO₂ | 164.0716 1.942 | HMDRD0000159 | 1.4046 | 3.00E-09 | 1.4346 | Up       | Amino acid metabolism                               |
| 26  | N-Lactoylphenylalanine | C₁₈H₃₄O₄N | 236.0926 2.009 | HMDRD0062134 | 1.7126 | 1.13E-08 | 1.4373 | Up       | Amino acid metabolism                               |
| 27  | N-Tryptophan | C₁₈H₃₄N₂O₂ | 203.0825 2.202 | HMDRD000929 | 1.3637 | 5.81E-08 | 1.3820 | Up       | Amino acid metabolism                               |
| 28  | 4-Hydroxybenzaldehyde | C₁₂H₂₀O₂ | 121.0294 2.552 | HMDRD0011718 | 1.1015 | 3.97E-06 | 1.2443 | Up       | Hydroxybenzaldehyde                                 |
| 29  | 5-HETE | C₁₉H₂₁N₂O₂ | 331.2374 10.186 | HMDRD001134 | 1.6689 | 1.77E-05 | 1.2122 | Up       | Arachidonic acid                                    |
| 30  | Palmitic acid | C₁₈H₃₄O₂ | 253.2325 16.203 | HMDRD000220 | 1.1220 | 5.70E-03 | 1.0388 | Up       | Fatty acid metabolism                               |
| 31  | Adrenic acid | C₁₈H₃₄O₂ | 331.2640 16.484 | HMDRD0002226 | 1.1945 | 2.57E-04 | 1.0614 | Up       | Biosynthesis of unsaturated fatty acid              |
signs of brain injury (Schaller and Graf, 2004). The present study revealed that after MCAO/R surgery and during the process of ischemia, NO (the precursor of peroxynitrite) and MDA (the product of lipid peroxidation) were significantly increased, which indicated a severe oxidative damage resulted from free radical and reactive oxygen species (ROS). Meanwhile, because of the imbalance of antioxidant systems, SOD, GSH, GSH-Px, and other antioxidant enzymes could be affected by the condition of cerebral ischemia reperfusion. Similar to the published data, the levels of SOD and GSH in rats of the MCAO/R group were significantly decreased (Chehaibi et al., 2016), whereas the activity of GSSG was obviously increased as compared with the SHAM rats (Kozer et al., 2003; Pradeep et al., 2012). Furthermore, histopathological results revealed that BMD had protective effects on brain injury by reducing the occurrence of neuronal loss, vacuolated spaces, and shrunken and disordered neurons. Meanwhile, there were no obvious side effects observed on each organ or mortality, suggesting the safety of BMD.

In order to obtain a better understanding of the effects of oxidative stress on IS, immunohistochemical examination was performed in the present study, which might provide a new visual angle for the prevention of IS. NF-κB was proved to regulate the transcription of genes related to stress, inflammatory, and growth responses. Meanwhile, NF-κB could promote ROS production and inflammatory responses after ischemic reperfusion (Sivandzade et al., 2019; Li et al., 2021). VEGF, a mediator of vascular permeability, was found to play an important role in the chronic neuro-inflammation. The key antioxidant genes such as SOD could be regulated by VEGF and thus might play an important role in brain damage and neuronal cell death (Chen et al., 2019b; Feng et al., 2019; Zhang et al., 2021). The previous study demonstrated that caspase-3 was a key indicative in the process of increased cell death, and the neuronal death due to oxidative stress might present an

![FIGURE 8](image)

**FIGURE 8**
Metabolite differences between serum and brain samples.

![FIGURE 9](image)

**FIGURE 9**
Differential metabolite changes in MCAO/R with BMD intervention in serum. Data were expressed as the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 relative to the MCAO/R group; **p < 0.01, ***p < 0.001 relative to the SHAM group.
increase in caspase-3 activation (Jing et al., 2020). In the present study, the expression of NF-κB and VEGF in the MCAO/R model group was obviously increased, and an increasing trend but no statistical significance of the caspase-3 level was observed in the MCAO/R model rats as compared with SHAM rats. After treatment with BMD, all of these had a certain improvement. Taken together, changes in oxidative stress played a crucial role in neuroprotective effects against IS injury.

Currently, researchers are increasingly relying on metabolomics to understand the etiology and pathogenesis of IS (Johnson et al., 2016). In this case, UHPLC-QTOF-MS/MS-based metabolomics was carried out to evaluate the protective effects and the possible mechanisms of BMD on MCAO/R rats by employing serum and brain metabolite profiling. A total of 22 differential metabolites in serum and 31 in brain samples between SHAM and MCAO/R groups were identified, and 30 of which were reversed after BMD intervention. These 30 metabolites were mainly related to seven metabolisms, including phenylalanine metabolism, histidine metabolism, tryptophan metabolism, arginine and proline metabolism, glycerophospholipid metabolism, fatty acid biosynthesis, and aminoacyl-tRNA biosynthesis. Amino acids played an important role in IS, and it was found to be involved in many important regulation metabolic processes in organisms (Li et al., 2019). Phenylalanine metabolism, histidine metabolism, tryptophan metabolism, and arginine and proline metabolism are
four primary metabolic ways that belong to amino acid metabolism. In this study, the levels of phenylalanine, histidine, tryptophan, valine, and proline were significantly increased in rats of the MCAO/R group as compared to the SHAM rats, suggesting that perturbed amino acid metabolism was implicated in IS. Phenylalanine played a key role in the biosynthesis of cells and tissues, and its hydroxylase could catalyze phenylalanine to tyrosine and further degrade to metabolic products to participate in the tricarboxylic acid cycle (Flydal and Martinez, 2013). More importantly, it could be used for the diagnosis of IS which might further accelerate brain injury and the course of disease (Goulart et al., 2019). Histidine, a precursor of histamine, was an amino acid with antioxidant activity, which was significantly effective in protecting nervous system injury (Tang et al., 2007; Bae and Majid, 2013). Tryptophan metabolism was recognized as a key regulator in the immune system, and an increased kynurenine/tryptophan ratio was proved to be related to neurocognitive function (Ketelhuth, 2019; Hajsl et al., 2020). Previous publications reported that arginine and proline metabolisms took part in many inflammatory diseases, which are integrally linked to cellular metabolism (Xie et al., 2021). Taken together, amino acid metabolism was closely associated with IS, and in our present study, the expression of 20 amino acids in rats of the MCAO/R model group was imbalanced as compared with that in SHAM rats, while BMD could apparently reverse these abnormal metabolites, suggesting that the metabolic disorder in vivo could be regulated by the early intervention of BMD.

As the structural components of biological membranes, phospholipids are mainly composed of glycerophospholipids and sphingolipids, which participated in signal transduction (Farooqui et al., 2007). Glycerophospholipid metabolism involved in a lot of living processes, and glycerophospholipid could be classified into six categories, such as PC, PE, and PI according to its different biological functions. Disturbed glycerophospholipid metabolism generally resulted in the rapid production and accumulation of free fatty acid and lysophospholipid, and
the IS injury caused by excitotoxicity and neuroinflammation was often accompanied by changes in the lysophospholipid level (Choi and Chun, 2013). In this study, metabolites such as lysoPC (14:0/0:0), lysoPC (20:5 (5Z,8Z,11Z,14Z,17Z)/0:0), lysoPC (18:1 (11Z)/0:0), lysoPE (15:0/0:0), lysoPE (18:0/0:0), lysoPI (18:0/0:0), and lysoPC (16:1 (9Z)/0:0) were all significantly decreased in the MCAO/R group as compared to the SHAM rats. It was worth noting that the changes in the aforementioned metabolites in the MCAO/R rats were all significantly improved after intervened with BMD. All of the results emphasized the importance of amino acid metabolism and glycerophospholipid metabolism in IS and also implied the beneficial effects of BMD on MCAO/R rats.

Having said all of the aforementioned factors, the significant changes in the oxidative stress index, such as NO, SOD, MDA, GSH, and GSSG, indicated excessive ROS production and abnormal oxidative status in MCAO/R rats. ROS was thought to be one of the triggering events for membrane phospholipid degradation in cellular membranes, which was associated with the accumulation of glycerol (Hillered et al., 1998). ROS could also alter protein metabolism or catabolism, thus leading to their degradation into amino acids. As a result, significant changes in the levels of amino acids in MCAO/R rats were observed (Batch et al., 2014). Therefore, the expression of amino acid metabolism and glycerophospholipid metabolism was influenced by oxidative stress to some extent.

5 Conclusion

In summary, the present study was the first time to explore the protective effects of BMD on the MCAO/R rat model of IS and the possible mechanisms by the integration of pharmacodynamics and metabolomics. Our results demonstrated that BMD intervention attenuated MCAO/R-induced IS symptoms and brain injuries, as well as improved oxidative stresses. Serum and brain metabolomic profiling suggested that the regulation of amino acid metabolism and glycerophospholipid metabolism had greatly contributed to the neuroprotective effects of BMD. Taken together, BMD might be a potential candidate for IS prevention and treatment.
Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

Ethics statement

The animal study was reviewed and approved by the Bioethics Committee of Ningxia Medical University.

Author contributions

XM: conceptualization, project administration, funding acquisition, and supervision. JC: conceptualization, funding acquisition, and writing—review. LY and XS: writing—original draft, validation, and methodology. FL: investigation, writing—original draft, and data presentation. RZ: validation and visualization/data presentation. SD: methodology, conceptualization, and investigation. JL: data presentation, validation, and investigation. GW: writing: refinement. LL and YY: sample collection and supervision and data analysis. WW: data analysis, investigation, and methodology. XW: validation, data presentation, and methodology. All authors agree to be accountable for all aspects of the final version of the manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (Nos. 81860753, 81560684, and U20A20136) and the Natural Science Foundation of Ningxia (2022AAC03201).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.1005301/full#supplementary-material

References

Bae, O. N., and Majid, A. (2013). Role of histidine/histamine in carnosine-induced neuroprotection during ischemic brain damage. Brain Res. 1527, 246–254. doi:10.1016/j.brainres.2013.07.004
Batch, B. C., Hyland, K., and Svetkey, L. P. (2014). Branch chain amino acids: Biomarkers of health and disease. Curr. Opin. Clin. Nutr. Metab. Care 17 (1), 86–89. doi:10.1097/MCO.000000000000010
Chehaibi, K. P., Trabelsi, I. P., Mahdouani, K. P., and Slimane, M. N. P. (2016). Correlation of oxidative stress parameters and inflammatory markers in ischemic stroke patients. J. Stroke Cerebrovasc. Dis. 25 (11), 2585–2593. doi:10.1016/j.jstrokecerebrovasdis.2016.06.042
Chen, R., Lee, C., Lin, X., Zhao, C., and Li, X. (2019a). Novel function of VEGF-B as an antioxidant and therapeutic implications. Pharmacol. Res. 143, 33–39. doi:10.1016/j.phrs.2019.03.002
Chen, R., Xu, Y., Wu, P., Zhou, H., Lasanajak, Y., Fang, Y., et al. (2019b). Transplantation of fecal microbiota rich in short chain fatty acids and butyric acid treat cerebral ischemic stroke by regulating gut microbiota. Pharmacol. Res. 148, 104403. doi:10.1016/j.phrs.2019.104403
Chen, W., Hu, Y., Jiang, L., Fang, G., Yang, B., Li, J., et al. (2021). Nanomedicines, an emerging therapeutic regimen for treatment of ischemic cerebral stroke: A review. J. Control. Release 340, 342–360. doi:10.1016/j.jconrel.2021.10.020
Cheon, S. Y., Kim, E. J., Kim, J. M., and Koo, B. (2018). Cell type-specific mechanisms in the pathogenesis of ischemic stroke: The role of apoptosis signal-regulating kinase 1. Oxid. Med. Cell. Longev. 2018, 2596043–2596049. doi:10.1155/2018/2596043
Choi, J. W., and Chun, J. (2013). Lysophospholipids and their receptors in the central nervous system. Biochim. Biophys. Acta 1831 (1), 20–32. doi:10.1016/j.bbalip.2012.07.015
Dírnel, U., Iadecola, C., and Moskowitz, M. A. (1999). Pathobiology of ischemic stroke: An integrated view. Trends Neurosci. 22 (9), 391–397. doi:10.1016/s0166-2236(99)01401-0
Farooqui, A. A., Horrocks, L. A., and Farooqui, T. (2007). Interactions between neural membrane glycerophospholipid and sphingolipid mediators: A recipe for neural cell survival or suicide. J. Neurosci. Res. 85 (9), 1834–1850. doi:10.1002/jnr.21268
Feng, S. Q., Zeng, S. Y., Liu, J. X., Chen, Y., Xu, R., Yin, X., et al. (2019). VEGF antagonism attenuates cerebral ischemia/reperfusion-induced injury via inhibiting endoplasmic reticulum stress-mediated apoptosis. Biol. Pharm. Bull. 42 (5), 692–702. doi:10.1248/bpb.b18-00628
Fjeldal, L., Kurz, K. D., Roy, S., and Kurz, M. W. (2015). Evaluation of the recombinant tissue plasminogen activator pretreatment in acute stroke patients with large vessel occlusions treated with the direct bridging approach. Is it worth the effort? Eur. J. Neurol. 22 (2), 322–327. doi:10.1111/ejn.12569
Flydal, M. I., and Martinez, A. (2013). Phenylalanine hydroxylase: Function, structure, and regulation. iubmb Life 65 (4), 341–349. doi:10.1002/iub.1150
Gairolla, J., Kler, R., Modi, M., and Khurana, D. (2017). Leptin and adiponectin: Pathophysiological role and possible therapeutic target of inflammation in ischemic stroke. Rev. Neurosci. 28 (5), 295–306. doi:10.1515/revneuro-2016-0055

Gouart, V., Sena, M. M., Mendes, T. O., Menezes, H. C., Cardeal, Z. L., Paiva, M., et al. (2019). Amino acid biosignature in plasma among ischemic stroke subtypes. Biomed. Res. Lett. 2019, 8480468. doi:10.1155/2019/8480468

Hajil, M., Hlavackova, A., Broulikova, K., Sramek, M., Malý, M., Dyr, J. E., et al. (2020). Tryptophan metabolism, inflammation, and oxidative stress in patients with neurovascular disease. Metabolites 10 (5), E208. doi:10.3390/metabo10050208

Hillerod, L., Valtrayson, J., Einblad, P., and Persson, I. (1998). Interstitial glycerol as a marker for membrane phospholipid degradation in the acutely injured human brain. J. Neurol. Neurosurg. Psychiatry 64 (4), 486–491. doi:10.1136/jnp.64.4.486

Jing, S. Q., Wang, S. S., Zhong, R. M., Zhang, J. Y., Wu, J. Z., Tu, Y. X., et al. (2020). Neuroprotection of Cyperus esculentus L. Osmotin against cerebral ischemia/reperfusion induced brain injury. Neural Regen. Res. 15 (3), 548–556. doi:10.4103/1673-5374.266063

Johnson, C. H., Ivanisevic, J., and Siuzdak, G. (2016). Metabolomics: Beyond biomarkers and towards mechanisms. Nat. Rev. Mol. Cell. Biol. 17 (7), 451–459. doi:10.1038/nrm.2016.25

Jurcau, A., and Ardelean, I. A. (2021). Molecular pathophysiological mechanisms of ischemia/reperfusion injuries after recanalization therapy for acute ischemic stroke. J. Integr. Neurosci. 20 (3), 727–744. doi:10.31083/jjin2003078

Ketelhuth, D. (2019). The immunometabolic role of indoleamine 2,3-dioxygenase in atherosclerotic cardiovascular disease: Immune homeostatic endothelial cell drive. Cardiovasc. Res. mechanisms in the artery wall. J. Neuroimmune Pharmacol. 15 (3), 556–566. doi:10.1016/j.jin2003078

Kozer, E., Evans, S., Barr, J., Greenberg, R., Soriano, I., Buklowestin, M., et al. (2003). Glutathione, glutathione-dependent enzymes and antioxidant status in erythrocytes from children treated with high-dose paracetamol. Br. J. Clin. Pharmacol. 55 (3), 234–240. doi:10.1046/j.1365-2125.2003.01723.x

Li, F., Xu, D., Hou, K., Gou, X., Lv, N., Fang, W., et al. (2021). Pretreatment of indobufen and aspirin and their combinations with clopidogrel or ticagrelor alleviates inflammation mediated pyroptosis via inhibiting NF-κB/NLRP3 pathway in ischemic stroke. J. Neuroimmune Pharmacol. 16 (4), 835–853. doi:10.1007/s11481-020-00978-9

Li, X., Kumar, A., and Carmellet, P. (2019). Metabolic pathways fueling the endothelial cell drive. Annu. Rev. Physiol. 81, 483–503. doi:10.1146/annurev-physiol-020518-114731

Nagasawa, H., and Kogure, K. (1989). Correlation between cerebral blood flow and histologic changes in A new rat model of middle cerebral artery occlusion. Stroke 20 (8), 1037–1043. doi:10.1161/01.str.20.8.1037

Oak, T., Potey, C., Maestriu, I., Petrazzi, M., Mendyk, A. M., Leys, D., et al. (2019). Neutrophils in tpa-induced hemorrhagic transformations: Main culprit, accomplice or innocent bystander? Pharmacol. Ther. 194, 73–83. doi:10.1016/j.pharmthera.2018.09.005

Pradeep, H., Diya, J. B., Shashikumar, S., and Rajanikant, G. K. (2012). Oxidative stress—assassin behind the ischemic stroke. Folia Neuropathol. 50 (3), 219–230. doi:10.5114/fin.2012.30522

Qureshi, M. I., Vorkas, P. A., Coupland, A. P., Jenkins, I. H., Holmes, E., and Davies, A. H. (2016). Lessons from metabolomics on the neurobiology of stroke. Neuroscientist 23 (4), 374–382. doi:10.1177/1073858416673327

Schaller, B., and Graf, R. (2004). Cerebral ischemia and reperfusion: The pathophysiological concept as A basis for clinical therapy. J. Cereb. Blood Flow. Metab. 24 (4), 351–371. doi:10.1097/00004467-200404000-00001

Swandzade, F., Prasad, S., Bhalerao, A., and Cucullo, L. (2019). NRF2 and NF-κB interplay in cerebrovascular and neurodegenerative disorders: Molecular mechanisms and possible therapeutic approaches. Redox Biol. 21, 101059. doi:10.1016/j.redox.2018.11.017

Song, X. (2007). Textual research on Huihui prescription. Beijing: Zhonghua Book Company.

Strong, K., Mathers, C., and Bonita, R. (2007). Preventing stroke: Saving lives around the world. Lancet. Neurol. 6 (2), 182–187. doi:10.1016/S1474-4422(07)70031-5

Tang, S. C., Arumugam, T. V., Cutler, R. G., Jo, D. G., Magnus, T., Chan, S. L., et al. (2007). Neuroprotective actions of A histidine analogue in models of ischemic stroke. J. Neurochem. 101 (3), 729–736. doi:10.1111/j.1471-4159.2006.04412.x

Xie, S., Jiang, S., Zhang, H., Wang, F., Liu, Y., She, Y., et al. (2021). Prediction of sublingual immunotherapy efficacy in allergic rhinitis by serum metabolomics analysis. Int. Immunopharmacol. 109, 107211. doi:10.1016/j.intimp.2020.107211

Yang, L., Qian, J., Yang, B., He, Q., Wang, J., and Weng, Q. (2021). Challenges and improvements of novel therapies for ischemic stroke. Front. Pharmacol. 12, 721156. doi:10.3389/fphar.2021.721156

Zhang, C., Zhen, L., Fang, Z., Yu, L., Zhang, Y., Wei, H., et al. (2021). Adiponectin treatment attenuates cerebral ischemia-reperfusion injury through HIF-1α-Mediated antioxidation in mice. Oxid. Med. Cell. Longev. 2021, 5531048. doi:10.1155/2021/5531048